MarketResearchNest.com adds “Herpes Zoster (Shingles) – Pipeline Review, H2 2017” new report to its research database. The report spread across 62 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) – Pipeline Review, H2 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.
Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
Browse full table of contents and data tables at
The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1, 5, 1 and 1 respectively.
Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
ContraVir Pharmaceuticals Inc, Epiphany Biosciences Inc, Foamix Pharmaceuticals Ltd, GeneOne Life Science Inc, GlaxoSmithKline Plc, Merck & Co Inc, NAL Pharmaceuticals Ltd, NanoViricides Inc, SK Chemicals Co Ltd, XBiotech Inc.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262558
Featured News & Press Releases
Jul 10, 2017: NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
Jun 26, 2017: NanoViricides Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology
Jun 21, 2017: GSK Presents Positive Results from Phase III Revaccination Study of its Candidate Shingles Vaccine Shingrix at CDC’s Advisory Meeting
Jun 21, 2017: Positive Phase 3 for GSK’s Shingles Vaccine Shingrix with Agenus QS-21 Stimulon Immune Adjuvant
Jun 06, 2017: NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Feb 24, 2017: In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles – Follows regulatory submissions in US and Canada
Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Herpes Zoster Therapeutics on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain